With the increased use of cell therapy in the veterinary sector, there is a growing demand for the development of cell-based medicinal products and the determination of their safety. Currently, the Korean Animal and Plant Quarantine Agency has established a guideline for evaluating the safety of cell-based medicinal products for animal use. The guideline includes items related to definition, classification, management, manufacturing procedure and quality control (standard and test method), stability testing, toxicity testing, pharmacological testing, and performance of clinical trials. In addition, testing protocols related to safety assessment of animal cell-based products such as chromosome karyotyping, tumorigenicity testing, confirmatory testing of biodistribution and kinetics, and target animal safety testing are described in detail. Moreover, because cell-based medicinal products are novel therapies, deviations from traditional designs may be justified in order to obtain relevant safety information on the treatment. Additionally, this guideline can be amended on the basis of new scientific findings.
MANUFACTURING METHOD STANDARDS AND TEST METHODS
The safety of CBMP should be ensured primarily through quality control according to the manufacturing method of the corresponding product, its manufacturing standards, and the associated test method. Therefore, the following should be documented in accordance with the relevant provisions of CBMP contained in the Regulation on Safety and Efficacy Evaluation for Veterinary Medicinal Products (APQA Notice No. 2018-5) [1] .
• Manufacturing process related to cell origin, cell collection (extraction and selection), freezing, thawing, primary culture, secondary culture and filling of cells, and its quality control requirements (storage conditions and periods, etc.) • Specific screening information on the cell donor animals (whether the animals had infectious diseases, genetic mutations, etc.) • Evidence of the absence of bacteria, fungi, mycoplasma, endotoxins, or adventitious viruses throughout the manufacturing process
STABILITY TESTING
Stability tests should be conducted according to the testing standard for long-term storage presented in the Guideline on Stability Testing for Veterinary Medicinal Products (APQA Notice). However, as it can be difficult to apply the general stability testing protocol due to the characteristics of CBMP, stability testing may be carried out by an appropriate test method that considers the characteristics of each product. In such a case, the storage method and expiration date shall be established by confirming the product's cell viability and potency through an appropriate stability test that considers the formulation, storage conditions, storage period, and transportation container and transport procedures (including temperature management) of the product, and the test's validity shall be documented. In particular, when a product is frozen or thawed, it shall be confirmed whether such product manipulations influence the stability or specifications of the product.
TOXICITY TESTING
Toxicity tests shall be conducted in compliance with the Guideline on Toxicity Testing for Veterinary Medicinal Products (APQA Notice No. 2016-22) [4] . However, as it can be difficult to apply the general toxicity testing protocol due to the characteristics of CBMP, toxicity testing may be carried out by using an appropriate test method that considers relevant regulations and the characteristics of each product. Furthermore, unlike general veterinary drugs, a combination of pharmacological and toxicity testing may be considered for CBMP.
Acute, subacute, and chronic toxicity testing 
Reproduction toxicity testing
When, during acute, subacute or chronic toxicity tests of a cell-based medicinal product, the corresponding cells are observed to be present in the gonads or reproductive tissues, or abnormalities in the reproductive system are confirmed, a reproductive toxicity test shall be conducted. The specific test methods should follow the relevant protocols of the Guideline on Toxicity Testing for Veterinary Medicinal Products.
Mutagenicity (or genotoxicity) testing
If a product has the potential to affect DNA or chromosomes, a mutagenicity test shall be conducted. However, the mutagenicity tests used for general veterinary drugs can be meaningless when applied for CBMP due to their characteristics. Therefore, mutagenicity testing can be conducted by confirming the transformation of cells other than the intended targets or by using a chromosome karyotyping test (Appendix 1) [5] .
Carcinogenicity (or tumorigenicity) testing
When a cell-based medicinal product has tumorigenic potential, such as a product derived from animal stem cells or cells confirmed to have abnormalities in a mutagenicity test, a tumorigenicity test shall be conducted using an immunodeficient animal or an equivalent animal, with the test having an observation period (12 weeks or longer) that is suitable for tumor formation in the target animal body (Appendix 2) [5] .
Local toxicity testing (or local tolerance testing)
A local toxicity test is conducted for clinical and histopathological evaluation at the injection site where a cell-based medicinal product is administered. This test may be conducted as an evaluation item within an acute, subacute, or chronic toxicity test.
Immunotoxicity testing (or confirmatory testing of immune system alteration)
When a cell-based medicinal product (limited to autologous cells) has the potential to cause an alteration in the immune system (e.g., changes in hematologic parameters, immunoglobulin levels, organ weights related to the immune system, etc.), an immunotoxicity test shall be conducted. Specific test methods shall follow the relevant test protocols of the Guideline on Toxicity Testing for Veterinary Medicinal Products. When there is no appropriate animal model, in vitro or ex vivo assays may be considered. Finally, this test needs to be included as an item in the evaluation of safety testing for the target animal.
Other special toxicity testing
A special toxicity test that is recognized as necessary according to the characteristics of the specific cell-based medicinal product shall be conducted.
PHARMACOLOGICAL ACTION TESTING
Pharmacological information for estimating the mechanism of action and efficacy of CBMP can be collected, but the data can only be used when the effectiveness of the corresponding products has been reasonably revealed by a review of domestic and foreign literature or knowledge. Furthermore, when a pharmacological action test of a cell-based medicinal product is conducted, it can be combined with toxicity testing; in such a case, the test methods and evaluation criteria should be scientifically and rationally validated.
Efficacy testing
In principle, efficacy testing shall be conducted using an appropriate test animal that can support the mechanism of pharmacological action and the effectiveness of the cell-based medicinal product. The efficacy test should demonstrate the expression, persistence, and effects of the product's pharmacological action. The efficacy test may be conducted as an additional item in the pharmacological action test when using a target animal or an appropriate animal model of the disease of interest.
General pharmacological testing
When a cell-based medicinal product or cell-derived bioactive substances other than the intended target are predicted to have adverse effects on the central nervous system, cardiovascular system, or respiratory system, a general pharmacological test shall be conducted to determine the effects on each system and function.
Testing for absorption, distribution, metabolism, and excretion
A confirmatory test of the biodistribution and kinetics, such as engraftment, proliferation, and persistence in multiple tissues, of a cell-based medicinal product shall be conducted using a target animal or an appropriate animal model of the disease of interest. In particular, when a cell-based medicinal product acts in a specific area (tissue type, etc.), its area or tissue localization should be demonstrated [2] . The test methods and evaluation criteria should be scientifically and rationally validated (Appendix 3). Guideline on evaluation for cell therapy
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CLINICAL TRIALS (INCLUDING TARGET ANIMAL SAFETY TESTING)
In principle, a clinical trial shall be conducted using a target animal or an appropriate animal model of the disease of interest (considering efficacy, compatibility, immune compatibility, etc.) only when it is unavoidable in accordance with the Guideline on Clinical Trial Management for Veterinary Medicinal Products (APQA Notice No. 2015-29) [6] . It is recommended that clinical trials should be conducted according to the approved protocol in order to obtain test results that are suitable for verifying the efficacy of the cell-based medicinal product and assessing its safety. When safety testing in a target animal is conducted, an appropriate test plan and evaluation items should be determined after considering the characteristics of each product and the guideline on target animal safety for veterinary pharmaceutical products excluding veterinary biologics (VICH GL43) of the Veterinary International Cooperation on Harmonization (VICH) [3, 7, 8] . Appendix 4 contains information on the standard test methods.
Overview
The mutagenicity tests used for general veterinary drugs can be meaningless for CBMP due to their characteristics. Rather, as the genomic stability of the cells constituting CBMP may be highly correlated with the tumorigenicity of the products, it is necessary to evaluate their mutagenicity. Therefore, the following presents standard protocols for chromosomal karyotyping tests that can be used to assess the genomic stability of CBMP.
Test methods (G-banding or Giemsa banding karyotyping)
Preparation of cells
For chromosomal karyotype analysis, the cells that constitute the CBMP should be sub-cultured in tissue culture flasks at 37°C with 5% CO 2 and air. Assaying should be conducted when the cultures attain 50% to70% confluence. 
Harvest of cells in metaphase of mitosis
Fabrication of slide samples
It is recommended that slide samples should be fabricated on the day of the harvest of cells in mitosis. The concentration of the cell suspension should be appropriately adjusted by using a fixative solution (1:3 ratio of cell layer to the fixative solution), and two slide samples should be fabricated.
Staining
The fabricated slides should be dried at 55°C for 12 h or longer, and then undergo Giemsa staining (4%) or Leishman staining (4%).
• Giemsa Staining (4%) ① Dip the slides in a mixture solution* of 0.125% trypsin/0.9% NaCl for 30 sec. *Mixture solution of 0.125% trypsin/0.9% NaCl: 100 mL of 0.5% trypsin + 300 mL of 0.9% NaCl ② Stop the trypsin reaction by moving the slides to 0.9% NaCl immediately (repeat steps 1 and 2 twice). ③ Stain the slides with Giemsa staining solution* for 5 min.
*Giemsa staining solution: 485 mL of Gurr's buffer solution (phosphate buffer solution, pH 6.8) + 30 mL of Giemsa solution + 10 mL of acetone ④ After staining the slides, wash them with Gurr's buffer solution (repeat steps 3 and 4 twice). 
Detection method
Overview
Tumorigenicity testing of CBMP is based on animal experimentation that uses live test animals. In this study, it is important to select animal models that can survive for a sufficient time and that can allow for the development of a prediction of tumorigenic potential in clinical practice. As needed, the test may be conducted additionally using in vitro tests, etc.
Test methods
Test animal
Appropriate animals, for which CBMP can engraft in vivo and exhibit pharmacological activity, should be selected and should include both male and female animals. In order to prevent test animals from having an immune response to the product, it may be necessary to select animals with impaired immunity or immunodeficiency or to consider the administration of immunosuppressive agents.
Number of animals
The number of animals should be determined after considering the sensitivity of test animals, the test methods, and the precision of the examination items. At this time, the loss of animals due to sudden death during the test and the number of animals required for the evaluation of tumorigenesis should also be taken into consideration, and finally, the number of animals that enable interpretation of the tumorigenicity results should be determined. In general, more than ten animals of each sex per group shall be used.
Route of administration
In principle, the administration route that is applied in clinical practice should be used. At this time, it is important to administer CBMP to the test animals through the same route as that in clinical applications and to ensure that the products are engrafted and distributed within the same anatomical area. When the administration route is different from that used in clinical applications, the route deemed most similar should be selected, and the scientific basis, including reasons and feasibility, for the selected route should be presented.
Dose level
Test group and control group are to be tested. The test group should consist of three or more dose levels, with the highest recommended dose in clinical application being the lowest level. The highest dose should be determined as the maximum feasible dose (generally, 107) that can be administered to test animals. It is desirable for the middle dose to be the geometric mean of the highest and lowest doses.
Control group
The control groups consist of both negative and positive groups. For the positive control group, the tumor-forming cell lines should be selected from cell lines that are similar to the CBMP; whereas, for the negative control group, an appropriate form of solvent (excipient, etc.) should be used.
